XM02 vs Placebo and Neupogen in Breast Cancer Patients
Author Information
Author(s): Auro del Giglio, Alexandru Eniu, Doina Ganea-Motan, Eskender Topuzov, Heinz Lubenau
Primary Institution: Faculdade de Medicina do ABC, Santo André, Sao Paulo, Brazil
Hypothesis
Is XM02 more effective than placebo and equivalent to Neupogen in reducing severe neutropenia in breast cancer patients undergoing chemotherapy?
Conclusion
XM02 was superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia after chemotherapy.
Supporting Evidence
- XM02 reduced the mean duration of severe neutropenia to 1.1 days compared to 3.9 days for placebo.
- The incidence of febrile neutropenia was significantly lower in the XM02 group (12.1%) compared to placebo (36.1%).
- Both XM02 and Neupogen™ had similar safety profiles with no significant differences in adverse events.
Takeaway
This study found that a new drug called XM02 helps breast cancer patients recover from low white blood cell counts faster than a placebo and works just as well as an existing treatment.
Methodology
348 breast cancer patients were randomized to receive XM02, Neupogen™, or placebo during chemotherapy, with the primary endpoint being the duration of severe neutropenia.
Potential Biases
The study was not double-blind, which may introduce bias in treatment assessment.
Limitations
A true double-blind design was not feasible due to differences in drug formulation.
Participant Demographics
The majority of participants were female (99.3%), with a mean age of 51 years.
Statistical Information
P-Value
0.028
Confidence Interval
[-0.261, 0.316]
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website